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PV-10 is a 10% solution of Rose Bengal that is currently
being examined as a novel cancer therapeutic. We have
previously shown that intralesional (IL) injection of PV-10
into a single subcutaneous B16 melanoma tumor led to
regression of both the injected tumor and uninjected B16
lung lesions. Tumor regression correlated with the induc-
tion of systemic anti-melanoma T cell immunity. In mela-
noma patients, IL injection of PV-10 has led to regression
of treated lesions as well as untreated bystander lesions. In
this study, we have examined whether IL PV-10 and
co-inhibitory blockade could improve anti-tumor immu-
nity and regression of melanoma. B16 cells were injected
into C57BL/6 mice to establish one subcutaneous tumor.
Treatment of this lesion with a single IL injection of
PV-10 alone led to partial regression of the injected
B16 lesion. Systemic administration of anti-CTLA-4 or
anti-PD1 antibodies in combination with IL PV-10
resulted in increased tumor regression and improved
survival in this model. Treatment with PV-10 also led to
the induction of T cells that produced IFN-g (495 ±
198 pg/ml) in response to B16 cells but not to irrelevant
MC-38 cells. Combination therapy with IL PV-10 and
anti-CTLA-4 led to increased IFN-g responses to B16
(1235 ± 191 pg/ml, p < 0.05). In another experiment simu-
lating heavy tumor burden using a bilateral model, sys-
temic administration of anti-PD-L1 antibodies in
combination with IL PV-10 led to regression of the
injected B16 lesion as well as a bystander subcutaneous
lesion on the opposite flank (p < 0.01 compared to mice
treated with anti-PD-L1 antibodies or IL PV-10 alone).
Together, these studies support the induction of increased
tumor-specific immunity after co-inhibitory blockade in
combination with IL PV-10 therapy.
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